A case report of pancreaticoduodenectomy with en bloc celiac axis resection

Author:

Zhang Mengna1,Zhang Bin2,Zhao Ying ’an2,Wu Anle2,Ren Xuanlei2,Zheng Jianbo2,Zhu Jiyun2,Yu Jun3,Zheng Siming2

Affiliation:

1. Zhejiang University School of Medicine

2. Ningbo First Hospital

3. First Affiliated Hospital Zhejiang University

Abstract

Abstract

Objective: To summarize the clinical experience of a case report of pancreaticoduodenectomy (PD) with en bloc celiac axis (CA) resection for locally advanced pancreatic cancer. Methods: Clinical data of one patient with locally advanced pancreatic cancer who underwent pancreaticoduodenectomy with en bloc celiac axis resection after neoadjuvant chemotherapy and embolization of the proper hepatic artery in the Department of Hepatopancreatobiliary Surgery of the First Affiliated Hospital of Ningbo University in May 2023 were retrospectively analyzed. Results: This case was operated smoothly with an operative time of 535 min, and intraoperative bleeding of about 800 ml. Only short-term elevation of hepatic aminotransferase appeared in the postoperative period, which was improved by hepatoprotective and symptomatic treatments, and was discharged from the hospital at 20 days postoperatively, and no tumour recurrence has occurred in the follow-up so far. Conclusion: In patients with locally advanced pancreatic cancer with simultaneous invasion of the celiac trunk, common hepatic artery and hepatic innominate artery, total pancreaticoduodenectomy with en bloc celiac axis resection is safe and feasible in cases where neoadjuvant chemotherapy is effective and after establishing hepatic collateral circulation by preoperative embolization of the hepatic innominate artery. Meanwhile, more cases in more centers are needed to validate this conclusion.

Publisher

Springer Science and Business Media LLC

Reference16 articles.

1. Chinese Pancreatic Surgery Association, Chinese Society of Surgery, Chinese Medical Association (2021). Zhonghua wai ke za zhi [Chinese journal of surgery], 59(7), 561–577. https://doi.org/10.3760/cma.j.cn112139-20210416-00171

2. MIZ༲AHI JD, SU༲ANA ༲, VALLE JW, et al༎ Pancreatic cancer [J] ༎ Lancet, 2020, 395( 10242) : 2008 - 2020༎

3. Zhang XM, Zhang J, Fan H, He Q, Lang R. Feasibility of portal or superior mesenteric vein resection and reconstruction by allogeneic vein for pancreatic head cancer-a case-control study. BMC Gastroenterol 2018; 18: 49 [PMID: 29661201 DOI: 10.1186/ s12876-018-0778-y]

4. Evans DB, Farnell MB, Lillemoe KD, Vollmer C Jr, Strasberg SM, Schulick RD. Surgical treatment of resectable and borderline resectable pancreas cancer: expert consensus statement. Ann Surg Oncol 2009; 16: 1736–1744 [PMID: 19387741 DOI: 10.1245/s10434-009-0416-6]

5. Ghaneh P, Kleeff J, Halloran CM et al The impact of positive resection margins on survival and recurrence following resection and adjuvant chemotherapy for pancreatic ductal adenocarcinoma. Ann. Surg. 269(3), 520–529 (2019).

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线,采集、加工和组织学术论文而形成的新型学术文献查询和分析系统,可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容,当前同舟云学术共收录了国内外主流学术期刊6万余种,收集的期刊论文及会议论文总量共计约1.5亿篇,并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询!咨询电话:010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号  京ICP备18003416号-3